Literature DB >> 32267475

An Intrapatient Concordance Study of Mismatch Repair Protein Immunohistochemical Staining Patterns in Patients With Muir-Torre Syndrome.

Cuong V Nguyen1, Kevin J Gaddis2, Michael R Stephens3, John T Seykora3, Emily Y Chu3.   

Abstract

Importance: Appropriate use criteria for Muir-Torre syndrome (MTS) screening suggest that mismatch repair protein (MMRP) immunohistochemical (IHC) testing is usually appropriate in patients with 2 or more sebaceous neoplasms (SNs). While MTS is known to be caused by a germline mutation in mismatch repair genes, data are limited as to whether individual sebaceous tumors in these patients with multiple lesions show identical MMRP IHC staining patterns. Objective: To determine concordance of MMRP IHC staining patterns in lesions of patients with MTS who have multiple SNs. Design, Setting, and Participants: This retrospective single-center case series evaluated 38 SNs in 11 patients with MTS confirmed by genetic testing for MMRP IHC staining patterns. Tumor sites were classified as either facial or extrafacial. Data were collected between January 1, 2007, and January 1, 2018. Main Outcomes and Measures: In each patient, MMRP IHC staining patterns for SNs were compared with one another to evaluate intrapatient concordance between lesions, and to the patient's known germline mutation.
Results: A total of 11 patients (7 women and 4 men) with MTS, with a mean (SD) age of 59.3 (10.6) years at time of SN biopsy, were identified. There was high concordance between MMRP IHC staining results (2-4 lesions per patient) and the patient's mutation status, with 36 of 38 total lesions (95%) matching (sensitivity, 94.7%; 95% CI, 82.3%-99.4%). Extrafacial site tumors represented 16 of 38 total lesions (42%) and demonstrated 100% concordance of IHC results to germline mutation. Only 1 of 11 patients (9%) demonstrated discordant results, with both lesions in this patient occurring on a facial site. Conclusions and Relevance: In patients with known MTS, SNs present with highly concordant MMRP IHC staining profiles across multiple lesions. There is also a strong association with underlying germline mutations. A diagnosis of MTS might be supported by MMRP IHC when the pretest probability is high.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32267475      PMCID: PMC7142808          DOI: 10.1001/jamadermatol.2020.0433

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  12 in total

1.  Discordant Mismatch Repair Protein Immunoreactivity in Lynch Syndrome-Associated Neoplasms:  A Recommendation for Screening Synchronous/Metachronous Neoplasms.

Authors:  Rachel M Roth; Sigurdis Haraldsdottir; Heather Hampel; Christina A Arnold; Wendy L Frankel
Journal:  Am J Clin Pathol       Date:  2016-06-29       Impact factor: 2.493

2.  Immunochemistry screening for Lynch syndrome in colorectal adenocarcinoma using an initial two antibody panel can replace a four antibody panel.

Authors:  Toni O'Regan; Kai Chau; Michael Tatton; Tania Smith; Susan Parry; Ian Bissett
Journal:  N Z Med J       Date:  2013-09-13

3.  Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome.

Authors:  M M Entius; J J Keller; P Drillenburg; K C Kuypers; F M Giardiello; G J Offerhaus
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

Review 4.  Review of the current medical literature and assessment of current utilization patterns regarding mismatch repair protein immunohistochemistry in cutaneous Muir-Torre syndrome-associated neoplasms.

Authors:  Jason B Lee; Brandon R Litzner; Claudia I Vidal
Journal:  J Cutan Pathol       Date:  2017-08-29       Impact factor: 1.587

5.  Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms.

Authors:  Maegan E Roberts; Douglas L Riegert-Johnson; Brittany C Thomas; Colleen S Thomas; Michael G Heckman; Murli Krishna; David J DiCaudo; Alina G Bridges; Katherine S Hunt; Kandelaria M Rumilla; Mark A Cappel
Journal:  J Genet Couns       Date:  2012-12-06       Impact factor: 2.537

6.  Mismatch repair proteins expression and microsatellite instability in skin lesions with sebaceous differentiation: a study in different clinical subgroups with and without extracutaneous cancer.

Authors:  Anna Maria Cesinaro; Alessandro Ubiali; Pamela Sighinolfi; Gian Paolo Trentini; Francesca Gentili; Fabio Facchetti
Journal:  Am J Dermatopathol       Date:  2007-08       Impact factor: 1.533

Review 7.  The Muir-Torre syndrome: a 25-year retrospect.

Authors:  R A Schwartz; D P Torre
Journal:  J Am Acad Dermatol       Date:  1995-07       Impact factor: 11.527

8.  Evaluation of universal immunohistochemical screening of sebaceous neoplasms in a service setting.

Authors:  K Schon; E Rytina; J Drummond; J Simmonds; S Abbs; R Sandford; M Tischkowitz
Journal:  Clin Exp Dermatol       Date:  2018-01-14       Impact factor: 3.470

9.  Universal Versus Targeted Screening for Lynch Syndrome: Comparing Ascertainment and Costs Based on Clinical Experience.

Authors:  Mujde Z Erten; Luca P Fernandez; Hank K Ng; Wendy C McKinnon; Brandie Heald; Christopher J Koliba; Marc S Greenblatt
Journal:  Dig Dis Sci       Date:  2016-07-06       Impact factor: 3.199

10.  Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.

Authors:  Chad J Jessup; Mark Redston; Erin Tilton; Julie D R Reimann
Journal:  Hum Pathol       Date:  2015-10-31       Impact factor: 3.466

View more
  4 in total

1.  Error in Results Section.

Authors: 
Journal:  JAMA Dermatol       Date:  2020-09-01       Impact factor: 10.282

Review 2.  Immunotherapy for Non-melanoma Skin Cancer.

Authors:  Sophia Z Shalhout; Kevin S Emerick; Howard L Kaufman; David M Miller
Journal:  Curr Oncol Rep       Date:  2021-08-27       Impact factor: 5.075

Review 3.  Sebaceous Carcinoma Epidemiology and Genetics: Emerging Concepts and Clinical Implications for Screening, Prevention, and Treatment.

Authors:  Michael R Sargen; Gabriel J Starrett; Eric A Engels; Elizabeth K Cahoon; Margaret A Tucker; Alisa M Goldstein
Journal:  Clin Cancer Res       Date:  2020-09-09       Impact factor: 13.801

4.  Detection of MSH2 Gene Methylation in Extramammary Paget's Disease by Methylation-Sensitive High-Resolution Melting Analysis.

Authors:  Liu Dong; Yingfeng Zhu; Liting Wu; Qiaoan Zhang; Feng Xu; Xinju Zhang; Xiao Xu; Yiting Tang; Guoqiang Ren; Zhihua Kang; Ming Guan
Journal:  J Oncol       Date:  2021-11-01       Impact factor: 4.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.